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Abstract Experimental studies have demonstrated that botulinum neurotoxin
serotype A (BoNT/A) causes ﬂaccid paralysis by a multi-step mechanism. Follow-
ing its binding to speciﬁc receptors at peripheral cholinergic nerve endings, BoNT/A
is internalized by receptor-mediated endocytosis. Subsequently its zinc-dependent
catalytic domain translocates into the neuroplasm where it cleaves a vesicle-docking
protein, SNAP-25, to block neurally evoked cholinergic neurotransmission. We tested
the hypothesis that mathematical models having a minimal number of reactions and
reactantscansimulatepublisheddataconcerningtheonsetofparalysisofskeletalmus-
clesinducedbyBoNT/Aattheisolatedratneuromuscularjunction(NMJ)andinother
systems. Experimental data from several laboratories were simulated with two differ-
ent models that were represented by sets of coupled, ﬁrst-order differential equations.
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In this study, the 3-step sequential model developed by Simpson (J Pharmacol Exp
Ther 212:16–21,1980) was used to estimate upper limits of the times during which
anti-toxins and other impermeable inhibitors of BoNT/A can exert an effect. The
experimentally determined binding reaction rate was veriﬁed to be consistent with
published estimates for the rate constants for BoNT/A binding to and dissociating
from its receptors. Because this 3-step model was not designed to reproduce tempo-
ral changes in paralysis with different toxin concentrations, a new BoNT/A species
and rate (kS) were added at the beginning of the reaction sequence to create a 4-step
scheme.ThisunboundinitialspeciesistransformedataratedeterminedbykS toafree
species that is capable of binding. By systematically adjusting the values of kS,t h e
4-step model simulated the rapid decline in NMJ function (kS ≥ 0.01), the less rapid
onset of paralysis in mice following i.m. injections (kS = 0.001), and the slow onset
of the therapeutic effects of BoNT/A (kS < 0.001) in man. This minimal modeling
approach was not only veriﬁed by simulating experimental results, it helped to quan-
titatively deﬁne the time available for an inhibitor to have some effect (tinhib) and the
relation between this time and the rate of paralysis onset. The 4-step model predicted
that as the rate of paralysis becomes slower, the estimated upper limits of (tinhib) for
impermeable inhibitors become longer. More generally, this modeling approach may
be useful in studying the kinetics of other toxins or viruses that invade host cells by
similar mechanisms, e.g., receptor-mediated endocytosis.
Keywords Invitro data · Invivo data · Clinical data · Toxicodynamics ·
Stimulation-frequency dependence
Manuscript Classiﬁcation Animal pharmacokinetics/pharmacodynamics ·
Human pharmacodynamics · Simulation
Abbreviations
BoNT/A Botulinum neurotoxin type A
NMJ Neuromuscular junction
t10 Time-to-10% peak tension
tinhib Time at which ≥10% of unbound BoNT/A is present and available
for an inhibitor to exert some effect
Introduction
The neurotoxins from Clostridium botulinum and several related species represent
some of the most lethal substances known [1–3]. The signs and symptoms include
ﬂaccid paralysis of the voluntary muscles, respiratory distress and death. The onset
times and durations of paralysis depend on the serotype involved, the exposure route
and the intoxicating dose. As summarized in [4], the public is becoming increasingly
aware of the roles of botulinum neurotoxins as food poisoning agents, as potential
bioweapons [1,2,5,6], and as approved treatments for various neurologic indications
and other clinical uses [7]. Signiﬁcant resources [8,9] have been devoted to the large-
scale production of heptavalent botulism antitoxin [10]. Complementary research to
engineer and develop high-afﬁnity, monoclonal neutralizing antibodies is also being
conducted [11].
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The bacteria express these toxins as single chain polypeptides (MW ∼ 150kDa)
which are later post-translationally modiﬁed to form two chains (heavy, 100kDa and
light, 50kDa) that are covalently linked by a disulﬁde bridge. The C-terminal half of
the heavy chain speciﬁcally binds to extracellular acceptors at peripheral cholinergic
nerve terminals [12] that innervate striated and smooth muscles. A process resem-
bling receptor-mediated endocytosis internalizes the toxin-bound receptor. As the
intravesicular environment becomes acidic (pH 5), the N-terminal half of the heavy
chainhelpsformcation-selectivechannelsthatmaybeinvolvedinallowingtheescape
of the toxic moiety (presumably the catalytic light chain or its derivatives) into the
neuroplasm (reviewed in [13]). The toxic fragment is a zinc-dependent protease that
cleaves at distinct sites and in a serotype-speciﬁc manner one or more of the SNARE
proteins (SNAP-25, syntaxin and VAMP) involved in the synaptic vesicle-mediated
release of acetylcholine. Once internalized, BoNT is no longer susceptible to circulat-
ingneutralizingantibodiesorotherimpermeableinhibitorsofitstoxicity.Thishomol-
ogous family of proteins are grouped into seven immunologically distinct serotypes
(BoNT/A-G) [3,14]. SNAP-25 is cleaved by BoNT serotypes A, E and C1, syntaxin
is cleaved by BoNT/C1, and VAMP is cleaved by the remaining BoNT serotypes [14].
The present study was designed to extend a data-driven minimal model devel-
oped by Simpson [15] that described the kinetics of botulinum neurotoxin serotype A
(BoNT/A) at the neuromuscular junction (NMJ) in producing paralysis invitro. This
original deterministic model consisted of a sequence of reactions based on the known
mechanismofBoNT/Aaction,namely,bindingtospeciﬁcreceptorslocatedatcholin-
ergic nerve terminals, translocating into the neuroplasm and, in turn, exerting a toxic
effect. All three steps were separately examined experimentally and quantitatively
characterized by apparent ﬁrst-order reaction rates. Modiﬁcations were introduced
in our study to allow for the changes in paralysis time course seen under different
invivo conditions [16–18]. We also developed a quantitative relationship between the
onset rate of paralysis and the time that is available to neutralizing antitoxins or other
non-permeable countermeasures to exert some inhibitory effect.
Methods
Reaction rates and other rate constants
The experimentally measured reaction rate of BoNT/A binding to the invitro NMJ
preparationmodelwascomparedtopreviouslydeterminedassociationanddissociation
(on and off) rate constants reported in [19] for rat brain synaptosomes. These micro-
scopic rate constants were adjusted for a ∼20◦C difference in temperature because
the NMJ experiments were conducted at 35◦C and the synaptosomal studies were
performed at 4◦C. The experimentally determined value for the temperature coefﬁ-
cient, Q10, for the binding step was used as the multiplicative factor by which a rate
constant is increased when increasing the temperature by 10◦C[ 20]. It was assumed
that the measured Q10 value was a constant for this 20◦C range of temperatures, that a
steady state of equilibrium was achieved and that toxin was not internalized following
binding.
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Reaction equations: 3-Step Model
The present models for the receptor binding, the nerve-terminal entry and the
subsequent toxic (lytic) activity of BoNT/A were developed using the same general
reaction schemes and numerical procedures that were previously used for modeling
thekineticsofneurotransmissionatperipheralandcentralsynapses[21,22].Reactions
describing the 3-step model were derived from [15] for BoNT/A intoxication at the
invitro rat NMJ:
free
kB →bound
kT →trans
kL →lytic (I)
where the system of coupled ﬁrst-order differential equations is:
d[free]/dt =− kB[free] (1a)
d[bound]/dt = kB[free]−kT[bound] (1b)
d[trans]/dt = kT[bound]−kL[trans] (1c)
d[lytic]/dt = kL[trans]. (1d)
This3-stepmodelrepresentsaminimalversionoftheoriginalmodelforafreeamount
of neurotoxin to bind, translocate into the neuroplasm and generate lytic activity [15].
Each species of BoNT/A is associated with a different environment: extracellular in
solution (free), on the surface, bound to a receptor (bound), intracellular endocytotic
vesicle (trans), and intracellular neuroplasm (lytic). The three irreversible steps even-
tuallyleadtotheblockadeofvesicle-mediatedneurotransmissionandthedevelopment
ofcompletemuscleparalysisintheNMJexperiments[15].Thebindingstepimplicitly
contains diffusion of free BoNT/A (0.1nM) to its binding sites at synaptic termini.
Theboundtoxinundergoestranslocationintotheneuroplasm.Intracellularly,thetoxic
moiety exerts it enzymatic proteolytic activity on SNAP-25 [14]. Embedded in this
species is the paralysis that occurs postsynaptically. Rates of reaction were taken from
[15] where kB = 0.058min−1, kT = 0.141min−1 and kL = 0.013min−1. This minimal
3-stepschemeisasimpliﬁcationfrom[15]becauseitomitsthreeunknownparameters
representing binding sites for each species of toxin. An analytic expression derived
for the lytic species,
lytic(t) =[ T]tot  
1 −
 
e−kTtkBkL (kB − kL) − e−kLtkBkT (kB − kT) + e−kBtkLkT (kL − kT)
 
(kB − kL)(kB − kT)(kL − kT)
 
,
(1e)
was used to verify the selection of the time steps for the numerical solution and
to establish further conﬁdence in our minimal approach. [T]tot represents the total
normalized amount of toxin. Analytic expressions for the other species are available
from the Electronic Supplementary Material.
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Reaction equations: 4-Step Model
The 4-step model is an extension of the 3-step model. BoNT/A is present at t=0i n
the bulk solution (S) and the rate constant, kS, simulates the rate of movement of the
non-binding species of BoNT/A from the bulk medium to the extracellular solution
that surrounds the nerve termini:
bulk
kS →free
kB →bound
kT →trans
kL →lytic (II)
d[bulk]/dt =− kS[bulk] (2a)
d[free]/dt = kS[bulk]−kB[free]. (2b)
In the 3-step model, initial conditions (t=0) for the normalized molecular species
of BoNT were [free]=1.0, [bound]=0 and [lytic]=0, while in the 4-step model these
specieswereinitiallysettozeroandthe[bulk]=1.0.Asinthe3-stepmodel,ananalytic
expression was derived for the lytic species:
lytic(t)=[T]tot −
[T]tot
⎛
⎜ ⎜
⎝
e−kTtkBkLkS (kB − kL)(kB − kS)(kL − kS)−
e−kStkBkLkT (kB − kL)(kB − kT)(kL − kT)+
e−kLtkBkSkT (kB − kS)(kB − kT)(kS − kT)−
e−kBtkLkSkT (kL − kS)(kL − kT)(kS − kT)
⎞
⎟ ⎟
⎠
(kB − kL)(kB − kS)(kL − kS)(kB − kT)(kL − kT)(kS − kT)
.
(2c)
AnalyticexpressionsfortheotherspeciesinthismodelareavailablefromtheElec-
tronicSupplementaryMaterial.ValuesofkS weresystematicallychangedfrom0.0001
to 15min−1. In these models of invivo systems there is no explicit clearance (i.e., loss
oftoxinfromthosesystems),onlyanimplicitonethatisembeddedinthekS ratevalue.
It was assumed that the amount of BoNT that was injected intramuscularly became
distributed in the extra-vascular space, and was partially taken up by the circulatory
system or in various organs (e.g., liver, spleen, kidney) as has been demonstrated in
[4] following i.v. injections of BoNT. The kinetic parameters used in these minimal
models are tabulated at http://botdb.abcc.ncifcrf.gov.
Diaphragm muscle function (peak twitch amplitude induced by electrical stimula-
tion of the phrenic nerve) was deﬁned as the normalized amount of tension remaining
after the formation of the lytic species:
tension = 1.0 −[ lytic]. (3)
Values of t10 are the times at which the model predicts that the peak twitch tension
is10% ofthemaximum tension, i.e.,a90%reduction intension. Thislevel ofresidual
tensionwasusedintheseinvitroexperimentsbecausecompleteparalysisisdifﬁcultto
accuratelymeasure[15].Thetwitchresponsesweremeasuredafterexposureto300ng
(10−10M)BoNT/Ain20mlbathingchambersasinpreviousinvitroNMJstudies[23].
Nerve-muscle preparations were exposed to toxin-containing media that were made
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with 0.5mM Ca2+ and 5.0mM Mg2+ to prevent toxin internalization. After a 60min
incubation, the preparations were washed with saline then soaked in control medium.
Other response measures were used in the mouse invivo studies [7,17] and in
clinical studies [18]. In [7], time spent by mice on an exercise wheel was monitored
during the onset and recovery of the BoNT/A-induced paralysis (0.2–1.5ng). The
study in [17] measured toe abduction reﬂexes as the functional parameter affected by
the i.m. injection of ∼26ng of BoNT/A. In the clinical study [18], the patient reported
thealleviationofsubjectivesymptomsofcervicaldystoniafollowingi.m.injectionsof
BoNT/A which are 1–4ng according to [24] for this neurologic disorder. In all of the
simulations using these invivo data, the term “response” replaces “tension” in Eq. 3.
In this study, we estimated the upper limit of time that non-permeable inhibitors of
BoNT/A (e.g., an antibody) have some effect. The value of this available time (tinhib)
was operationally deﬁned as the time at which the amount of unbound BoNT/A is at
least 10% of the initial unbound species. We are using this metric from the point of
viewthatitisthetoxinthatneedstobeinhibitedbyanantibodyorothernon-permeable
inhibitor. Because tinhib is quantitative, it can be later reﬁned when the time course of
the unbound amount of BoNT/A is experimentally resolved. In the 3-step model, the
relative value of the unbound BoNT/A is equal to the value of the free species, while
in the 4-step model, the relative value of the unbound BoNT/A is equal to the sum of
the values of the free and the bulk species.
Computer programs and statistical methods
The kinetic schemes were visually constructed and edited interactively using
JDesigner which is part of the open source Systems Biology Workbench (SBW) [25].
This program saves models in SBML format so that they can be used as a front-end
software component to any SBW-compatible equation solver. The ordinary ﬁrst-order
differential equations describing the reactions built with JDesigner were solved by
Jarnac, a script language-based program for analyzing biochemical reaction networks
[25]. Mathematica (Wolfram Research Inc, Champaign, Illinois) generated analytic
expressions that were used to verify the selection of the time steps for the numeri-
cal solutions by Jarnac and to establish further conﬁdence in our minimal approach.
A spreadsheet-compatible data-analysis utility was used to digitize and store two-
dimensional coordinates of data points from selected ﬁgures shown in [4,7,15–17]
and [18] (Datatrend Software, Raleigh, North Carolina). Linear regression analy-
s i so ft h ef o r my = y 0+ax was performed on the data in Fig.2 to calculate coefﬁ-
cients of determination (R2) and values of the slope (a) and intercept (y0) along
with standard errors of the mean (S.E.M.) using SigmaPlot (ver. 9.01, 2004, Sys-
tat Software, Inc., Chicago, Illinois). Area under the curve (AUC) calculations were
performed on the numerical outputs (Fig.1) by summing the amount of free toxin
(ng units) present at each time increment (60min) in the 3-step model. Because
of the small amount of free toxin predicted for the simulation in Fig.4, only the
amount of bulk toxin was summed at each time increment (1min) in the 4-step model.
Elimination rates of the unbound (i.e., free or bulk) toxin species were calculated
by taking the amount (ng units) at t=0 and dividing by the AUC value (min-ng
units).
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Results
Relating the binding reaction rate to the receptor binding and dissociation
rate constants for BoNT/A
Before examining the 3-step model, we tested the hypothesis that the receptors for
BoNT/A are not saturated at 0.1nM, the concentration used in [15]. In addition, we
evaluated the relation between the measured apparent ﬁrst-order binding reaction at
the rat NMJ (kB) [15] and the association (kon) and dissociation (koff) microscopic
rateconstantsthathavebeenmeasuredusingratcerebrocortical-derived,synaptosome
preparations [19]. The values for kon = 0.0138nM−1min−1 and koff = 0.0072min−1
at 4◦C[ 19] correspond to a Kd =0 . 5 2n M .[ 15] the rate of paralysis in the rat NMJ
preparation (kB = 0.058min−1 was measured under conditions of low [Ca2+], high
[Mg2+] containing solutions at 35–36◦C to block the internalization step (Fig. 2 of
[15])).Inkeepingwithexperimentalobservations[15],itwasassumedthatlow[Ca2+],
high [Mg2+]-containing solutions did not affect these on and off rate constants in this
reversible reaction:
U + R
kon

koff
B (III)
where [U] = [BoNT/A](unbound), [R] = binding site (productive ecto-acceptor)
[26], and [B] = [BoNT/A](bound). Using the experimentally determined value for
Q10 = 1.6 for the binding step [15], the temperature-adjusted values for kon and koff
at 35◦C were estimated to be 0.056nM−1 min−1 and 0.029min−1, respectively, and
are used in the equations below. The total toxin and binding site concentrations at
t > 0a r e
[T]tot =[ U]+[B];[R]tot =[R]+[B]. (4)
The binding-site occupancy was assumed to be described by the mass-law formu-
lation to give an equilibrium dissociation constant
Kd =
koff
kon
=
[U][R]
[B]
(5)
in which the species concentrations are substituted for their activities. These terms
are related to the experimentally measured value for kB, an apparent ﬁrst-order rate
constant, that is the reciprocal of the relaxation time constant (τ) for a reversible,
single-step bimolecular reaction [27]:
kB = 1/τ = ([T]tot +[R]tot)kon + koff (6)
Combining and rearranging Eqs.4–6 yields a quadratic expression
[R]2 +{ 2Kd − kB/kon}[R]+(Kd[T]tot − KdkB/kon + K2
d) = 0( 7 )
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in which the positive root of [R]i s :
[R]=
−{2Kd − kB/kon}+
 
{2Kd − kB/kon)}2+4{Kd[T]tot − KdkB/kon+K2
d}
2
(8)
Solving for [R] allows values for [U] and [B] to be calculated
[U]=
([T]tot/Kd)
[R]+(1/Kd)
(9)
[B]=[ T]tot −[ U]. (10)
Using this approach with a dimensionless value of Ttot =1.0, the values for the
reaction species at 35◦C (assuming a steady state of equilibrium and no toxin inter-
nalization) were calculated to be [R]=8.6, [U]=0.69 and [B]=0.31. From these
results, the values of Kd and the corresponding on and off rate constants support the
ideathatthebindingsitesforBoNT/Aarenot saturated.These resultsalsosupportthe
hypothesis that the binding reaction rate for BoNT/A measured in the isolated NMJ
at 35–36◦C can be feasibly compared with the microscopic on/off rate constants for
BoNT/A measured in rat brain at 4◦C.
The 3-step model: estimates of tinhib and the frequency dependence of toxicity
at the NMJ
As depicted in Fig.1, the experimental data collected from the invitro NMJ (adapted
from Fig.4 of [15]) was simulated with a minimal 3-step model. In those experiments,
BoNT/Awasincubatedinlow-Ca2+,high-Mg2+ containing-mediafor40mintoallow
near-maximal binding. A second incubation period with normal media allowed for
near-maximal translocation (∼90% in 16min) which was followed by the commence-
ment of phrenic nerve stimulation to monitor the gradual decline in twitch tension.
In contrast, BoNT/A was applied in this and the 4-step model at t=0. The time
coursesofthefourBoNT/Aspeciescanbevisuallycomparedduringthedevelopment
of BoNT/A-induced paralysis (time-to-10% tension, t10=204min). The numerical
solution generated by Jarnac for the tension curve using a time step of 1min (Fig.1,
black line) was veriﬁed with an analytic expression (white curve superimposed on
black line, Eqs.1e and 3). The time course of the free BoNT/A species provides a
quantitative metric for estimating the time available for an inhibitor to exert some
effect (tinhib), as deﬁned in the Methods. In this 3-step model, t10 was predicted to be
ﬁve times longer than tinhib. This model predicted that to exert some degree of inhi-
bition, impermeable neutralizing antibodies or BoNT/A inhibitors need to be applied
within 40min of the addition of 0.1nM BoNT/A to the bathing chamber, i.e., before
a ∼20% reduction of nerve-evoked twitch tension occurs.
Theuse-dependence associatedwithBoNT/AattheNMJ(dataadapted fromFig.5
of [15]) is illustrated in Fig.2A in which paralysis times decreased (smaller values of
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Fig. 1 Simulation of experimental NMJ data with the 3-step model. The time courses of the model species
can be compared with the development of BoNT/A-induced paralysis (ﬁlled symbols, data from [15]). The
time-to-10% tension, t10 , was 204min. The upper limit for the amount of time available for an inhibitor
of BoNT/A to exert some effect, tinhib,w a s≤40min (see Methods). All BoNT/A species are represented
as relative values. Dotted line: free BoNT/A; long dashes: bound toxin; short dashes: translocated species;
black line: amplitudes of peak twitch tension numerically calculated from the 3-step model; white line
(superimposed on black line): amplitudes of peak twitch tension calculated from Eq. 1e
t10) as the frequency of stimulating the phrenic nerve increased. Results of the linear
regression analysis (see Methods) were:
t10 = 94.6(5.4, S.E.M ) − 85.4(35.9, S.E.M. )frequency (R2 = 0.73).
ChangingthevaluesofeitherkB orkT couldonlypartiallysimulatetheexperimental
data. In contrast, altering the values for the third reaction rate (kL) could, for the ﬁrst
time to our knowledge, simulate the entire set of data associated with the frequency-
dependentenhancementofBoNT/A-inducedparalysis.Valuesfort10 (Fig.2B)overlap
with the experimental data points that reside within a linear portion of the predicted
non-linear relation between values of kL and normalized times-to-10% tension. The
valuesofkL (0.013–0.019min−1)correspondtovaluesofstimulationfrequenciesthat
are within practical experimental limits (Fig.2C):
frequency = 0.54(0.67, S.E.M. ) + 43.25(4.16, S.E.M. )kL (R2 = 0.98).
The 4-step model: invitro NMJ versus invivo systems and estimates for tinhib
Altering the three original reaction rates (kB,kT and kL) failed to produce the slower
onset rates of BoNT/A-induced paralysis observed invivo. Thus, the 3-step model
examined above was extended and used to simulate BoNT/A-induced responses of
patients when administered as an approved therapeutic product [18] and of mice when
injected as a local paralysant [7,17]. In this model, a new, initial reaction rate (kS) was
created that represents the movement of BoNT/A (bulk species) from distal locations
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Fig. 2 Different values of kL in
the 3-step model simulated the
frequency-dependence of the
rate of onset of BoNT/A-induced
paralytic activity. Panel A: plot
of data points where values for
t10 are expressed as normalized
values. Panel B: The 3-step
model (dashed line) produced a
non-linear relation between
kL(0.01 − 0.3min−1) and the
time-to-10% tension, t10. Within
the range of experimental data,
the plot was linear and at higher
values of kL approached an
asymptotic value for the
normalized values of t10. Panel
C: Values of kL were adjusted to
simulate normalized t10 values
at each of the four
experimentally used nerve
stimulation frequencies. Circles:
experimental data from Fig.4 in
[15]; lines in Panels A and C:
least-squares ﬁts drawn through
the data points
fromitsreceptorstotheproximalvolumewheretheBoNT/A(freespecies)isavailable
for binding.
Slow onset kinetics for the beneﬁcial effects of treatments using BoNT/A have
been published in the clinical literature. Normalized clinical data represented in
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Fig. 3 Different values of kS in the 4-step model simulated the onset of BoNT/A-induced effects in a
variety of invitro and invivo data sets. The onset of paralysis with bath-applied BoNT/A at the rat NMJ
(circles, from Fig.1) is rapid and is associated with kS values ≥0.01min−1. Invivo data (time using an
exercise wheel, see Methods) from locally injected mice (stars, data from [17]; upward triangles, data
from [7]) were simulated using kS =0.001min−1. Clinical data (subjective measure of relief of neurologic
symptoms, see Methods; downward triangles) are from a patient whose ﬁrst session of BoNT/A treatment
w a so nd a y0( d a t af r o m[ 18]). The maximum BoNT/A-induced effect, achieved by day 11, was simulated
with kS =0.00015min−1
Fig.3 are from a patient with cervical-dystonia-related complaints receiving BoNT/A
intramuscularly (data from Fig.1, injection series 1 in [18]).Starting at approximately
day 11, the maximum relief from symptoms was noted by the patient (t10= 10.6days).
The rate constant kSwas systematically varied from 0.0001 to 10min−1 to provide an
estimated value of 0.00015min−1 for this model.
Otherexamplesfromtwoseparateexperimentalstudiesusingmicearealsoincluded
in Fig.3 [7,17]. Both sets of data following local intramuscular injections could be
simulated (kS = 0.001min−1). These data show a more rapid onset than the clinical
data but are slower than the onset of paralysis seen with the invitro rat NMJ data (see
alsoFig.1).Inthis4-stepmodel,theNMJdatacouldbesimulatedwithvaluesofkS ≥
0.01min−1.
A comparison was also made of the time courses for the different toxin species in
the 3-step model for the NMJ and the 4-step model for the invivo data examined here.
As for the model tension prediction in Fig.1, the numerical solution for the tension
curve (Fig.4, black line) was veriﬁed analytically (Fig.4; white curve, Eqs. 2c and 3).
As mentioned above, the 3-step NMJ model predicted that the time-to-10% tension
(t10) was 5 times slower than tinhib. In contrast, the clinical data had a much slower
onset (t10 = 15,450min or 10.6days) for the BoNT-induced response, whose value
was almost identical to that of tinhib (Fig.4). In this case, unbound BoNT/A was com-
posedlargelyofthebulkspecieswithanegligiblepresenceofthefreeBoNT/Aspecies.
Thus,inthe4-stepmodelfortheclinicaldata,thetimecourseoftheunboundBoNT/A
species was predicted to develop at essentially the same rate as the time course of
paralysis.
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Fig. 4 Time-dependence of the BoNT/A species from the 4-step model that simulated the clinical data.
The time courses of the different species can be compared with the relatively slow loss of tension
(t10=15,450min or 106days) of BoNT/A-induced paralysis. In contrast to the invitro NMJ (Fig.1), the
time courses of the unbound BoNT/A and the lytic species overlapped, making the estimated upper limit
value of tinhib longer invivo than at the isolated NMJ. Closed circles: subjective clinical data from [18];
black line: responses were calculated numerically from the 4-step model using kS = 0.00015min−1; white
line: responses were calculated from Eq. 2c
The area under the curve (AUC) calculations were done to compare the temporal
proﬁles of the unbound species of BoNT using invitro NMJ and invivo human data.
TheareasforunboundBoNT/Aareaboutthesame(<20%difference)fortheisolated
NMJ and for the invivo injections in man. The NMJ was exposed to 300ng while
the patient received an i.m. injection of approximately 1 ng BoNT/A. The amount of
unbound BoNT at the NMJ decreased by 95% in 50min. In man, the same decrease
occurredinabout20,000min(400timeslonger).TheAUCfortheNMJis5174min-ng
using the 4-step model with kS > 0.01min−1, while the AUC for man is 6406min-
ng using the 4-step model with kS = 0.00015min−1.A st h ev a l u eo fk S decreased,
the amount of the unbound BoNT at any time point increased. Given the presumed
differences in toxin purities and the uncertainty in the amount the patient received,
these area values are remarkably similar. The rate of disappearance of the unbound
BoNT/A is 400 times faster at the NMJ but this preparation also received about 300
times more BoNT/A than the patient. Thus, the calculated areas are similar due to
offsetting differences in these rates and the amounts of toxin used.
To demonstrate the relation between the upper-limit estimate for tinhib and time-
to-10% tension (t10), the values of kS were varied (Fig.5). The symbols in this ﬁgure
are the same as in Fig.3 for representing kS values from the NMJ, from the i.m.
injections in mice and from the clinical data. The 4-step model predicted that as kS
decreased,theabsolutevaluesfort10 andtinhib increased.TherelationsbetweenkS and
the upper-limit estimates of tinhib and times-to-10% tension were non-linear (Fig.5A).
The largest component of the unbound BoNT/A species was predicted to be the bulk
species for the data from the mouse local injections and from the clinical data where
kS ≤ 0.001min−1. These calibration curves also provide upper-limit estimates for
tinhib that can be directly related to the duration for which a pre-deﬁned threshold of
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Fig. 5 Effects of varying kS on the upper-limit estimates of tinhib and onset times for BoNT/A-induced
paralysis. Panel A: the two durations, the times-to-10% peak tension (t10) and the tinhib, increase and con-
verge as the values of kS decrease. Panel B: the predicted concentration of unbound BoNT/A (decomposed
into bulk and free species) at tinhib, is dependent on the value of kS. The placement of symbols along the
x-axis in both panels (upward triangles, downward triangles, stars, and circles) are deﬁned in Fig.3 and
depict which of the unbound species and values of kS are associated with those simulations. For clarity,
these symbols were placed just above the x-axis to correspond with the appropriate values of kS
tensionissustained.TheplotsinFig.5BoverarangeofvaluesofkS showtherelative,
decomposed values for unbound BoNT/A at tinhib for the bulk and free species. The
same trends were obtained with this model at other levels of post-exposure tension
(50 and 90%) that were examined (data not shown).
Discussion
The results of this study support the hypothesis that a minimal approach can model
responses from invitro and invivo systems. This common tactic of using a reduction-
ist approach was applied because computing the BoNT/A-induced perturbations in
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nerve-evoked muscle twitches is beyond the practicality of developing fully detailed
models of the mechanisms of neurotoxin action upon vesicle-mediated chemical neu-
rotransmission. Several implicit assumptions were made in the two models examined.
Mostimportantly,itwasassumedforcomputationalconveniencethatthemodelswere
independentofcompartmentsandthatuniformdistributionsexistedforalltheBoNT/A
species and binding sites. Despite these simpliﬁcations and our incomplete knowl-
edge of cellular structures, relevant results emerged using biochemical observables
as guides, speciﬁcally, the binding reaction rate [15] together with the microscopic
bindinganddissociationrateconstants[19].Thesevalueswereconsistentwithclassic
methods in ligand-binding studies in which the inequality [R]tot > [T]tot is assumed
to exist within a well-stirred system that is far from a state of binding-site saturation
[28]. Our calculations also show that various types of binding data from different
tissues (central and peripheral neurons) and temperatures (4 to 35–36◦) are related.
More insights were gained using the minimal models about the temporal relations
between the extent of paralysis and the time that is available for an inhibitor to exert
some effect, tinhib, under different invitro and invivo conditions. These simulations
predicted upper-limit estimates for tinhib during which 10% of the maximum amount
of the unbound BoNT/A species is available for interacting with impermeable antag-
onists. Perhaps the most important concept to emerge from these minimal models is
that as the onset rate of paralysis becomes slower, i.e., as the value of kS decreases, it
also becomes a better indicator of the upper-limit for when tinhib and the times-to-10%
tension (t10) converge (Fig.5). The value of tinhib is not a static amount of time but,
rather, depends on the rate of paralysis onset.
These modeling results are related to a recent study of iatrogenic botulism. The
existence of detectable serum levels of BoNT/A (12–24mouse LD50) in three out of
four case-patients 2–3days following extremely high i.m. doses (up to eight million
mouse LD50) of research-grade toxin [29] suggests that the anti-toxin administration
may have had a beneﬁcial effect. These results also suggest that further development
of animal models need to be conducted invivo to test hypotheses that use onset rates
of paralysis to obtain accurate estimates of tinhib for neutralizing antibodies or imper-
meable, low molecular weight inhibitors.
The binding step for BoNT/A was intentionally simpliﬁed because of the inherent
complexity of the intoxication process and of the variety of reactions comprising
neurotransmission. At least two molecular components form the functional binding
site for BoNT/A, a protein and a ganglioside [14]. The ganglioside is GT1b or a
related derivative [30,31]. Although the protein component (SV2, synaptic vesicle
protein-2) has twelve putative transmembrane spanning regions [32,33], the location
of the BoNT/A binding site is on a region of SV2 that is within a synaptic vesicle.
This location implies that the interior solution of this structure must be in transient
contact with the extracellular medium so that BoNT/A can bind immediately or bind
following vesicle-pore closure and vesicle ﬁssion from the presynaptic membrane.
During quiescent periods, the majority of the BoNT/A SV2 binding sites are not in
contact with the extracellular medium and are unavailable for binding.
In contrast, with neural stimulation, these sites become exposed and available
for binding, and as the frequency of stimulation increases, the time-to-10% tension
(t10) decreases [15] (Fig.2). Although alterations in the other two reaction rates, by
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themselves, were insufﬁcient to simulate the examined data, changes in all three of
these reaction rates may be required to accurately model the experimental data. Thus,
the enhanced rate of paralysis onset with increased nerve stimulation frequency may
be a complicated function of enhanced calcium entry and an enhanced lytic effect,
i.e., the proteolysis of the BoNT/A substrate SNAP25.
Other simpliﬁcations of the binding process in the 4-step model involve the initial
step associated with the reaction rate, kS. As noted in [15], there are anatomical
and perhaps other barriers that interfere with BoNT/A readily diffusing to BoNT/A
binding sites in the isolated NMJ. For the simulations of both the short-term invitro
and longer-term invivo systems, delays in diffusion to binding sites caused by non-
speciﬁc binding [26,34] also need to be considered. Potential non-speciﬁc binders of
BoNT/A include serum proteins (e.g., albumin) [4] and extracellularly located sites in
the circulatory system.
Regarding the ﬁnal two steps in the minimal models, simpliﬁcations were made for
the translocation and lytic (toxic) processes [13,15,35,36]. The translocation step can
be decomposed into at least a dozen steps, the most prominent being vesicle ﬁssion
from the plasma membrane into the neuroplasm, the activation of energy-dependent
proton pumps with the subsequent decrease in intra-vesicular pH, the resultant con-
formational changes to BoNT/A, the reduction of its inter-chain disulﬁde bridge, the
ion channel formation by the toxin’s heavy chain, and the escape of the toxic moiety
(presumably the 50kD light chain) into the neuroplasm where it exerts its toxic effect.
A simpliﬁed single-step reaction is justiﬁed because the rates associated with many
of these reactions are, as yet, undetermined.
The simpliﬁed lytic process includes among its most important reactions the zinc-
dependent enzymatic activity of BoNT/A [15] that can be described by Michaelis-
Menten kinetics to cleave SNAP-25 [37]. This proteolysis prevents the formation of
a functional SNARE protein complex (including synaptobrevin, syntaxin and other
proteins) to block the release of acetylcholine and eventually block stimulus-evoked
musclecontractions.Thelyticstepalsocontainsasteepnon-linearrelationbetweenthe
amount of substrate cleaved and the decrease of the evoked muscle twitch amplitude
[38–40].
Althoughweselectedaclinicalstudythathadanabundanceofrelevantquantitative
data [18], other clinical cases involving onset time scales of days should also be
computationallyexaminedandcompared.Forexample,regardingcasesoffood-borne
[41],iatrogenicandwoundbotulism[42]thereisalackofextensiveclinicaldatasetsin
thepubliclyavailableliteratureandotheropensourcestoarchiveparalysistimecourses
for future studies evaluating the temporal dependence of treatment effectiveness.
Notwithstandingthelimitationsofourminimalmodels,theyhaveallowedustosim-
ulatetheonsetkineticsofBoNT/A-inducedeffectsobservedinexperimentalandclin-
ical studies. Beyond gaining a better appreciation of the temporal events that underlie
theharmfulaswellaspotentiallybeneﬁcialeffectsofthisfamilyofneurotoxins,these
models also provide us with an initial, quantitative framework for making extrapola-
tions from animal model to human data.
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